Verrica Pharmaceuticals, which is developing a drug-device that eliminates viral skin lesions and warts, raised $75 million by offering 5 million shares at $15, the midpoint of the $14 to $16 range. At the IPO price Verrica commands a fully-diluted market value of $290 million. Verrica Pharmaceuticals plans to list on the Nasdaq under the symbol VRCA. BofA Merrill Lynch, Jefferies and Cowen & Company acted as lead managers on the deal.
